Chimeric Therapeutics Ltd (CHM) — Strategic Asset Allocation Index
Chimeric Therapeutics Ltd (CHM) has a Strategic Asset Allocation Index of 0.0% as of June 2025. Strategic assets (PP&E of AU$0.00 plus long-term investments of AU$-) total AU$0.00, measured against net assets of AU$1.97 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check CHM cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Chimeric Therapeutics Ltd Strategic Asset Allocation Index (2021–2024)
This chart shows how Chimeric Therapeutics Ltd's Strategic Asset Allocation Index has evolved across 4 annual periods from 2021 to 2024. As of June 2025, the index stands at 0.0%, representing strategic assets of AU$0.00 against net assets of AU$1.97 Million AUD. See Chimeric Therapeutics Ltd leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Chimeric Therapeutics Ltd (2021–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for Chimeric Therapeutics Ltd from 2021 to 2024, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Chimeric Therapeutics Ltd stock valuation.
| Year | SAAI | Strategic Assets (AUD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 1.6% | AU$40.00K | AU$- | AU$40.00K | AU$2.47 Million | ▲ +0.8 pp |
| 2023 | 0.8% | AU$45.60K | AU$5.60K | AU$40.00K | AU$5.66 Million | ▲ +0.6 pp |
| 2022 | 0.2% | AU$55.99K | AU$15.99K | AU$40.00K | AU$25.71 Million | ▲ +0.2 pp |
| 2021 | 0.1% | AU$13.63K | AU$13.63K | AU$- | AU$25.13 Million | — |